Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit.
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
Pfizer’s $6.7 billion bet on Arena Pharmaceuticals has delivered a phase 3 success.
Recursion reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.
FierceBiotech Special Report: The top 10 biotech IPOs of 2021
Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage
BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of HER2 negative high-risk early-stage breast cancer
Company launches Precise™ Tumor test, part of a comprehensive suite combining germline, tumor and companion diagnostics in one easy-to-access solution
Acquisition offers new, differentiated, and potentially best-in-class approach to address needs of a broader number of patients with immuno-inflammatory diseases
PolarityTE Announces $5.0 Million Registered Direct Offering